TEL AVIV, June 15, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today reported comparative Phase 1 data evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results